Congress

Politics By Lev Facher

San Francisco, Austin, or Raleigh? White House contemplates an out-of-D.C. address for new biomedical research agency

Politics By Rachel Cohrs

Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill

Politics By Rachel Cohrs

Senate Democrats eye drug pricing policies to fund $3.5 trillion budget deal

D.C. Diagnosis By Nicholas Florko

Biden wants a drug pricing plan in 45 days. Who’s going to write it? 

Politics By Rachel Cohrs

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

D.C. Diagnosis By Nicholas Florko

Operation Warp Speed — now, the ‘CAG’— is here to stay

First Opinion By James K. Glassman

Biden won’t end cancer — or any other disease — by importing drug price controls from Europe

Politics By Nicholas Florko

Bipartisan pair of senators calls on Congress to examine expensive new Alzheimer’s drug 

Politics By Nicholas Florko

Key Democrats slam FDA for failing to crack down on Juul and other e-cigarette makers

Politics By Nicholas Florko and Rachel Cohrs

Key science officials detail their plans for a new research agency — and Congress is getting closer to funding it 

Politics By Nicholas Florko

Powerful Democrat’s new drug pricing manifesto hints at a carveout for small biotechs

Pharmalot By Ed Silverman

Lawmakers revive legislation to accelerate the development of new antibiotics

Politics By Rachel Cohrs

Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates

Pharmalot By Ed Silverman

Senate finance chair investigates AbbVie over its corporate tax strategy

Pharmalot By Ed Silverman

Lawmakers pitch a bill to create $30 billion in ‘biobonds’ to jumpstart drug development

Politics By Rachel Cohrs

Health care providers hope to cash in through Congress’ new earmark process

Politics By Nicholas Florko

Democrats call on FTC to investigate AbbVie’s Humira pricing strategy

Politics By Nicholas Florko

Congress is ready to grill AbbVie’s CEO over drug pricing 

Exclusive By Nicholas Florko

Abandoned Trump order on the bioeconomy highlights a path forward for Biden — but with mixed reviews 

Politics By Rachel Cohrs and Casey Ross

Telehealth companies are fueling a lobbying frenzy to protect their Covid boom

Exclusive By Nicholas Florko

Key House Democrats’ push for a ‘bipartisan’ drug pricing bill could doom Pelosi’s signature legislation

Pharmalot By Ed Silverman

Pharmalittle: Pharma showers a key Democratic senator with cash; Lilly exec accused of altering factory documents

Politics By Nicholas Florko

Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms 

Politics By Rachel Cohrs

Biden’s Medicaid pressure tactics could put his team at odds with hospitals

Politics By Rachel Cohrs

Top Senate Democrat heads back to drawing board on drug pricing